[go: up one dir, main page]

WO2001042790A3 - Mittel und verfahren zur diagnose von lyme borreliose sowie borreliose-impfstoff - Google Patents

Mittel und verfahren zur diagnose von lyme borreliose sowie borreliose-impfstoff Download PDF

Info

Publication number
WO2001042790A3
WO2001042790A3 PCT/EP2000/012454 EP0012454W WO0142790A3 WO 2001042790 A3 WO2001042790 A3 WO 2001042790A3 EP 0012454 W EP0012454 W EP 0012454W WO 0142790 A3 WO0142790 A3 WO 0142790A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
borrelia
burgdorferii
borrelia burgdorferii
homologue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2000/012454
Other languages
English (en)
French (fr)
Other versions
WO2001042790A2 (de
Inventor
Peter Jungblut
Aydan Dilgimen
Sascha Thies
Brigitte Wittmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
WITA GmbH Technologiezentrum Teltow
Original Assignee
WITA GmbH Technologiezentrum Teltow
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by WITA GmbH Technologiezentrum Teltow filed Critical WITA GmbH Technologiezentrum Teltow
Priority to EP00991154A priority Critical patent/EP1238280A2/de
Publication of WO2001042790A2 publication Critical patent/WO2001042790A2/de
Publication of WO2001042790A3 publication Critical patent/WO2001042790A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/20—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Die Erfindung betrifft Mittel zur Diagnose und/oder Therapie von Lyme Borreliose enthaltend die Antigene Glyceraldehyd-3-phosphat-Dehydrogenase (GAPDH), Oligopeptid-Permease, Oligopeptid ABC transporter periplasmic BP(oppA-2)(Bb), Glycosyl transfase IgtD homolog, heat shock Protein 90, VLSE fragment, (U76406) putative v1s rec. casette V1s6 Borrelia burgdorferii, Flagellin Protein Borrelia garinii, (AE001578) conserved hypothetical protein cp32-6 Borrelia burgdorferii, membrane assoc. protein p66 precursor Borrelia burgdoferii, Oligopeptid ABC transporter periplasmic BP (oppA-4)(Bc), Fructose-biphosphate aldose (fba) Borrelia burgdorferii, DNAK Protein Heat Shock Protein 70 Borrelia burgdorferii, orfE Borrelia burgdorferii, Outer surface protein B precursor Borrelia burgdorferii, L-lactate dehydrogenase (ldh), P83/100 gene Borrelia burgdorferii, Enolase 2phosphoglycerat Borrelia burgdorferii, Flagellin Protein Borrelia garinii, hypothetical protein BBE28 Borrelia burgdorferii, DNA direct. RNA polymase (rpoA) homolog, P66 protein (fragment), Flagellin (fragment), DNA direct. RNA polymase, integral outer membran protein p66, pyruvate kinase (pyk) homolog; Phosphoglycerat kinase (pgk) und/oder BBU28760 NID und/oder deren Fragmente und/oder für die Antigene und/oder Fragmente codierenden Nucleinsäuresequenzen.
PCT/EP2000/012454 1999-12-08 2000-12-08 Mittel und verfahren zur diagnose von lyme borreliose sowie borreliose-impfstoff Ceased WO2001042790A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP00991154A EP1238280A2 (de) 1999-12-08 2000-12-08 Mittel und verfahren zur diagnose von lyme borreliose sowie borreliose-impfstoff

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19960113A DE19960113A1 (de) 1999-12-08 1999-12-08 Mittel und Verfahren zur Diagnose von Lyme Borreliose sowie Borreliose-Impfstoff
DE19960113.5 1999-12-08

Publications (2)

Publication Number Publication Date
WO2001042790A2 WO2001042790A2 (de) 2001-06-14
WO2001042790A3 true WO2001042790A3 (de) 2001-12-06

Family

ID=7932515

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/012454 Ceased WO2001042790A2 (de) 1999-12-08 2000-12-08 Mittel und verfahren zur diagnose von lyme borreliose sowie borreliose-impfstoff

Country Status (4)

Country Link
US (1) US20030138868A1 (de)
EP (1) EP1238280A2 (de)
DE (1) DE19960113A1 (de)
WO (1) WO2001042790A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL223175B1 (pl) 2012-10-22 2016-10-31 Inst Chemii Bioorganicznej Polskiej Akademii Nauk Szczepionka przeciw boreliozie, konstrukt genetyczny, rekombinowane białko, sposób otrzymywania konstruktu genetycznego, sposób otrzymywania szczepionki, sposób otrzymywania rekombinowanych białek, zastosowanie rekombinowanych białek do wytwarzania szczepionki przeciwko boreliozie
AU2017254665C1 (en) 2016-04-20 2021-03-11 Centro de Investigaciones Energeticas, Medioambientales Y Tecnologicas, O.A., M.P. Compositions and methods for enhanced gene expression of PKLR
CN105920593A (zh) * 2016-06-08 2016-09-07 山东省海洋生物研究院 一种水产迟钝爱德华氏菌亚单位口服微胶囊疫苗
WO2018083491A1 (en) 2016-11-03 2018-05-11 University Of Leicester Phage-based detection of borreliosis and means therefor
EP3410117A1 (de) * 2017-06-02 2018-12-05 Université de Strasbourg Nachweis von borrelia burgdorferi sensu lato bei patienten mit disseminierter late-lyme-infektion
JP7403461B2 (ja) 2017-10-16 2023-12-22 セントロ デ インベスティガシオンス エネルジェチカス メディオアンビエンタゥス イェ テクノロジカス オー．エイ． エム．ピー． ピルビン酸キナーゼ欠損症を治療するためのｐｋｌｒ送達用レンチウイルスベクター

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000448A1 (en) * 1991-06-28 1993-01-07 The Regents Of The University Of California Methods and compositions for diagnosing lyme disease
WO1995014781A2 (en) * 1993-11-24 1995-06-01 The University Of Connecticut Methods for diagnosing early lyme disease
WO1997026273A1 (en) * 1996-01-22 1997-07-24 The Regents Of The University Of California Borrelia burgdorferi outer membrane proteins
WO1997042325A1 (en) * 1996-05-08 1997-11-13 Yale University B. burgdorferi polypeptides expressed in vivo
EP0821237A2 (de) * 1996-07-22 1998-01-28 Immuno Ag Immunassay zum Nachweis von anti-B. burgdorferi Antikörpern und Verfahren zur Serodiagnose bei Lyme Borreliose, diagnostische Mittel und Testkits zur Durchführung der Verfahren
EP0949508A1 (de) * 1998-04-08 1999-10-13 Dako A/S Verfahren, Antigen-Komplex und Satz zur Diagnose Lyme-Borreliose

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000448A1 (en) * 1991-06-28 1993-01-07 The Regents Of The University Of California Methods and compositions for diagnosing lyme disease
WO1995014781A2 (en) * 1993-11-24 1995-06-01 The University Of Connecticut Methods for diagnosing early lyme disease
WO1997026273A1 (en) * 1996-01-22 1997-07-24 The Regents Of The University Of California Borrelia burgdorferi outer membrane proteins
WO1997042325A1 (en) * 1996-05-08 1997-11-13 Yale University B. burgdorferi polypeptides expressed in vivo
EP0821237A2 (de) * 1996-07-22 1998-01-28 Immuno Ag Immunassay zum Nachweis von anti-B. burgdorferi Antikörpern und Verfahren zur Serodiagnose bei Lyme Borreliose, diagnostische Mittel und Testkits zur Durchführung der Verfahren
EP0949508A1 (de) * 1998-04-08 1999-10-13 Dako A/S Verfahren, Antigen-Komplex und Satz zur Diagnose Lyme-Borreliose

Also Published As

Publication number Publication date
WO2001042790A2 (de) 2001-06-14
EP1238280A2 (de) 2002-09-11
DE19960113A1 (de) 2001-06-13
US20030138868A1 (en) 2003-07-24

Similar Documents

Publication Publication Date Title
Alm et al. Analysis of the genetic diversity of Helicobacter pylori: the tale of two genomes
Nelson et al. Complete genome sequence of the oral pathogenic bacterium Porphyromonas gingivalis strain W83
Davies et al. Characterisation of bovine strains of Pasteurella multocida and comparison with isolates of avian, ovine and porcine origin
Vasiliu et al. Heterogeneity of Borrelia burgdorferi sensu lato demonstrated by an ospA-type-specific PCR in synovial fluid from patients with Lyme arthritis
Furuya et al. Specific amplification of Rickettsia tsutsugamushi DNA from clinical specimens by polymerase chain reaction
WO2002012294A3 (en) Group b streptococcus polypeptides nucleic acids and therapeutic compositions and vaccines thereof
JP2008513022A5 (de)
WO2000078966A1 (en) Groups of borrelia burgdorferi and borrelia afzelii that cause lyme disease in humans
KR20070101197A (ko) 유전자와 단백질들, 및 그들의 사용
EP1219711A3 (de) Lawsonia intracellularis Impfstoff
Purta et al. YgdE is the 2′‐O‐ribose methyltransferase RlmM specific for nucleotide C2498 in bacterial 23S rRNA
WO2003082183A2 (en) Protein-based streptococcus pneumoniae vaccines
WO2001042790A3 (de) Mittel und verfahren zur diagnose von lyme borreliose sowie borreliose-impfstoff
Li et al. Identification of secreted proteins as novel antigenic vaccine candidates of Haemophilus parasuis serovar 5
WO2002016422A3 (en) Recombinant constructs of borrelia burgdorferi
Collinson et al. The location of four fimbrin-encoding genes, agfA, fimA, sefA and sefD, on the Salmonella enteritidis and/or S. typhimurium XbaI-BlnI genomic restriction maps
Baril et al. Scattering of the rRNA genes on the physical map of the circular chromosome of Leptospira interrogans serovar icterohaemorrhagiae
Amouriaux et al. Polymerase chain reaction with the 30-kb circular plasmid of Borrelia burgdorferi B31 as a target for detection of the Lyme borreliosis agents in cerebrospinal fluid
WO2003058248A3 (en) Diagnostics and vaccines for mycrobacterium paratuberculosis infections
Radu et al. Molecular characterization of Vibrio cholerae O1 and non-O1 from human and environmental sources in Malaysia
WO2005026200A3 (en) Lawsonia intracellularis subunit vaccine
Cullen et al. Characterization of a locus encoding four paralogous outer membrane lipoproteins of Brachyspira hyodysenteriae
Linton et al. Comparison of random amplified polymorphic DNA with restriction fragment length polymorphism as epidemiological typing methods for Mycobacterium tuberculosis
WO1998004585A3 (en) Novel human macrophage antigen
WO2000006742A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): CA US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

WWE Wipo information: entry into national phase

Ref document number: 2000991154

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000991154

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10149532

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2000991154

Country of ref document: EP